# data[].attributes.body
Reklaam räägib ,et on leidnud koroona viirusele ravimi ja üritab seda müüa kalli hinna eest kuid teadlased ei leidnud mingit sidet koroona viiruse ravimiseks või immuunseks tegemiseks selle ravimiga. Ravim on ilmselgelt toodetud vanemate inimeste ja noorte laste emadele kes ei usalda vaktsiini ja ravim kasutab neid ära raha pärast.

# data[].attributes.attachment_link.readable_text
The results of early studies from the US and China, which show disappointing results in the use of an antimalarial drug and an anti-retroviral drug in treating Covid-19, will not impact trials of the drug under way in Australia, researchers say.

To date more than 300 clinical trials in humans are under way around the world to investigate treatments for the virus, with several of these occurring in Australia. Among the most hyped drugs are hydroxychloroquine, an antimalarial which is also used to treat people with painful autoimmune conditions, and lopinavir and ritonavir, both antiretroviral drugs. Antibiotics are also being studied.

But a study of Covid-19 hospital patients given hydroxychloroquine in the US found no benefit from the drug, either alone or given in combination with an antibiotic. In fact, the patients treated with hydroxychloroquine alone had a higher mortality rate. Meanwhile, researchers in China found that neither lopinavir or ritonavir showed any benefit in patients admitted to hospital with mild-to-moderate cases of the disease.

'A lot still to learn'

The findings come as all patients with Covid-19 being admitted to intensive care at the Royal Brisbane and Women's hospital in Queensland are being given hydroxychloroquine as part of their treatment. Neither the Queensland department of health nor the hospital responded to multiple requests for comment from Guardian Australia as to whether the trial would be reassessed in light of evidence from overseas.

A separate study, known as Ascot (AustralaSian COVID-19 Trial), is under way in more than 70 Australian hospitals and will test whether lopinavir/ritonavir and hydroxychloroquine, alone or in combination, prevents deterioration of Covid-19 patients. A leader of the Ascot study, Prof David Paterson, said despite the disappointing findings from the US, the Australian study would go ahead. The US study was retrospective and conducted in a relatively small group of patients, whereas the Ascot study is being conducted as a randomised control trial, the strongest type of study and the gold standard for evidence.

"The conclusions of the authors of the US study were that randomised trials are needed," Paterson said. "This is exactly what we are undertaking with Ascot. Many commentators have observed that the US study was observational in design, and that it may have been that people who were not very sick were given no treatment and therefore had a greater chance of surviving, while those who were very sick and were at a greater intrinsic chance of dying were given hydroxychloroquine or other treatments in desperation.

"There is clearly a lot still to learn about treatments for Covid-19. Large randomised clinical trials like Ascot are the only way to do this."

A federal Department of Health spokesman said the government was closely monitoring the results of studies from around the world investigating treatment or preventions for Covid-19.

"The clinical evidence base is currently limited and results from large, prospective and controlled studies are required before the efficacy and safety of hydroxychloroquine is better understood," he said. "Clinical trials in Australia are conducted by a sponsor who has overall responsibility for the trial, with oversight by a human research ethics committee. Within the bounds of a clinical trial, safety is carefully monitored and the sponsor and committee can halt a trial at any time should serious safety issues emerge."

'Panic causing bad decisions'

However, despite advice from the Australian Health Protection Principal Committee that experimental use of medications is not recommended for Covid-19, and should only be prescribed as part of a clinical trial, some hospitals around Australia are giving the drugs to critically unwell patients outside of trials. This differs from advice from the drugs regulator, the Therapeutic Goods Administration, that the drugs can be given as part of clinical trials or to severely unwell Covid-19 patients.

Infectious diseases physician and former adviser to the World Health Organization, Prof Peter Collignon, said this was concerning.

"I think this is an indication of panic causing bad decisions," he said.

"Even in the face of evidence showing it's doing no good we continue to use these drugs. Of course, doctors are able to use drugs off-label. But if it's clearly shown - and I think the evidence is showing this for hydroxychloroquine - that it's doing more harm, then it should be unethical to give patients these drugs outside of a trial."

He added that ethics committees should be constantly reviewing approvals of clinical trials as evidence emerges.

Dr Gaetan Burgio, an Australian National University infectious disease specialist ,said given the lack of proven efficacy and the potential serious toxicity on seriously unwell patients, he also believes hydroxychloroquine should not be administered to patients outside of clinical trials.

However, he said there was no reason to stop Australian clinical trials as a result of the findings from overseas so far. "In my view, as the patients are a well controlled clinical setting and thoroughly monitored, there is no reason to halt them."

Maintaining scientific standards

Australian states and territories have differed in their approach to off-label use of drugs to treat Covid-19. In Western Australia and Victoria, there is no off-label or experimental use of medications for patients outside of clinical trials. The Queensland department of health said chloroquine, hydroxychloroquine and lopinavir-ritonavir have been used on selected patients across Queensland, but did not confirm whether these patients were part of clinical trials. NSW Health did not respond to a request for comment.

The proliferation of studies examining treatments for Covid-19 prompted bioethicists Dr Jonathan Kimmelman and Prof Alex John London to write, in the international journal Science, that crises "are no excuse for lowering scientific standards". They wrote that regulatory agencies "should also avoid making public recommendations or granting emergency use authorisation for interventions whose clinical merits remain to be established and, instead, present clinical trials as a mechanism for addressing uncertainty without compromising patient interests".

On Monday, the Medical Journal of Australia published a piece summarising randomised trials under way to treat Covid-19. Led by the Menzies School of Health Research, it said "the near-instant dissemination of information and opinion that is prevalent in today's world makes properly designed clinical trials more important than ever".

Currently, there are no approved treatments for Covid-19. Patients are given supportive care, for example ventilation, if breathing significantly deteriorates.

# data[].attributes.attachment_link.title
Australian hydroxychloroquine trials continue despite studies showing no benefit to coronavirus patients

# data[].attributes.attachment_link.description
The results of early studies from the US and China, which show disappointing results in the use of an antimalarial drug and an anti-retroviral drug in treating Covid-19, will not impact trials of the drug under way in Australia, researchers say.

# data[].attributes.body
Lugu räägib et Austraalia mees leidis koroonale ehk COVID 19le ravimi ja küsib hullu raha selle eest. Kui selline asi oleks olemas siis arstid oleks juba selle leidnud

# data[].attributes.attachment_link.readable_text
Australia's drug regulator, the Therapeutic Goods Administration, has dropped its investigation into newspaper advertisements taken out by the former federal politician Clive Palmer that described a drug unproven in the treatment of Covid-19 as a "cure".

In March, the TGA confirmed it was looking into Palmer's two-page ad in the Australian and on Facebook that stated the drug, hydroxychloroquine, when combined with another medication could "wipe out the virus in test tubes". The ad also quoted the leader of a clinical trial, Prof David Paterson, saying it was not a stretch to describe the drug as a cure. Drug advertising rules state any therapeutic claim made in relation to novel coronavirus must be supported by appropriate evidence and must not mislead.

The ad said Palmer had agreed to personally fund the acquisition or manufacture of 1m doses "to ensure all Australians would have access to the drug as soon as possible". On Tuesday, Palmer paid for another series of ads in News Corp papers stating he had since bought 32.9m doses of the drug. The federal government confirmed Palmer has a "written arrangement" with the government to acquire the drug for the national medical stockpile.

The Therapeutic Goods Administration said neither the latest ads nor the previous ones were being investigated. "Assessment of Mr Clive Palmer's advertisements have been concluded and enforcement action is not warranted," a TGA spokesman said. "The information was assessed as not intended to promote the sale of the product."

The latest advertisements ran in newspapers including the Daily Telegraph and the Mercury, and said hydroxychloroquine was Australia's best hope for Covid-19 sufferers. The Royal Australian College of General Practitioners has warned against viewing the drug as a treatment. The college president, DrHarry Nespolon, said "trials are ongoing and my understanding is that they are not looking particularly promising ".

"The problem here is that people may think that a cure is imminent and be lulled into a false sense of security so that they don't exercise social distancing responsibilities," Nespolon said. The drug can also cause severe and life-threatening side-effects.

The University of Queensland's Prof David Paterson, who Palmer quoted in his first series of ads as describing the drug as a cure, said his comments had been taken out of context.

"My comments that the drugs could be a potential treatment or cure for Covid-19 were based on previous research on coronaviruses such as Sars and preliminary data from China and Singapore on Covid-19," Paterson told the Guardian on Monday. "To formally establish the efficacy and safety of these drugs large clinical trials are needed."

The university edited its original press release online on 18 March about the clinical trial, in which Paterson described the treatment as a "potential cure for all", to remove that statement.

On 16 March, Paterson had appeared on The Project. When asked by Waleed Aly if it was correct to describe the drug as a "cure" rather than just a treatment, Paterson responded: "Absolutely."

There are no approved treatments for Covid-19. Patients are given supportive care, for example ventilation, if breathing significantly deteriorates. A retrospective study of Covid-19 hospital patients given hydroxychloroquine in the US found no benefit from the drug, either alone or given in combination with an antibiotic. The study found patients treated with hydroxychloroquine alone had a higher mortality rate.

# data[].attributes.attachment_link.title
Clive Palmer ad for coronavirus 'cure' cleared by Australian drug regulator

# data[].attributes.attachment_link.description
Australia's drug regulator, the Therapeutic Goods Administration, has dropped its investigation into newspaper advertisements taken out by the former federal politician Clive Palmer that described a drug unproven in the treatment of Covid-19 as a "cure".

# data[].attributes.body
Viimati uuendatud 25.juuli 2019. Veebi lehe eest vastutab organisatsioon Lõunaeestlane ja autorid on sammuti nemad. Lugu räägib tänapäeva laste tervisest.

# data[].attributes.attachment_link.readable_text
Viimasel ajal on eriti tugevalt ühiskonnas tõstatunud laste heaolu temaatika, mida on kajastatud nii laste elutingimuste kui ka laste murede vaatevinklist. Tervise Arengu Instituudi laste ja noorte valdkonna nooremteadur Karin Streimann kirjutas artikli laste vaimse tervise olukorrast, mis nähtub läbi teadusuuringute. Karin puudutab oma artiklis ka ennetusprogramme, mis on olulised laste probleemide ärahoidmisel ja on võtmeks, kuidas aidata meie lapsi.
Kuidas läheb meie lastel?
Rahvuse ja kultuuri tugevus ning säilimine sõltub sellest, kui hästi või kehvasti läheb lastel. Viimasel ajal meedias laia kajastust leidnud artiklid on viidanud vägivallale ja vaimse tervise probleemidele koolilaste elus. Kas sellised mured on laialt levinud, kuidas üldse läheb meie lastel?

Mõnes valdkonnas läheb neil väga hästi. Pidevalt näitena välja toodav PISA (2015) uuring näitab, et Eesti põhikooliõpilaste tase on maailma parimate seas ning kõigil on üsna võrdsed võimalused heale haridusele. Viimane kooliõpilaste tervisekäitumise uuring (TAI, 2019) näitab kaasõpilaste kiusamist kogevate kui kaasõpilasi kiusavate laste arvu vähenemist. Samas on viimasel paaril kuul teisi kiusanud iga neljas ning kiusamist kogenud iga kolmas õpilane. Ligi 40 protsenti 11-, 13- ja 15-aastastest õpilastest ei pea kooliskäimist meeldivaks ning iga kümnes tunneb, et talle üldse ei meeldi koolis käia.

Lastel on teisigi muresid. Näiteks on ajas kasvanud kooliõpilaste depressiivsus. Kui 2009./2010. aastal oli seda aasta jooksul kogenud iga neljas laps, siis 2017./2018. aastal juba iga kolmas. Mida vanemaks lapsed saavad, seda kehvemini nad end tunnevad. Märgatavalt kehvemaks on muutunud 15-aastaste noorte vaimne tervis, kellest iga viies on aasta jooksul mõelnud ka enesetapule. Maailma Terviseorganisatsiooni hinnangul saab enamus noorte surmadest, näiteks suitsiidid, narkootikumide üledoosid, alguse vaimse tervise probleemidest.
Eesti õpilased proovivad teistest varem alkoholi ja kanepit
Kehva vaimse tervise põhjuseid võib olla mitmeid, kuid laste igakülgset arengut mittetoetavad keskkonnad suurendavad nii kiusamist, meeleoluhäirete esinemist kui ka alkoholi, tubakatoodete ja narkootikumide tarvitamist. Viimase osas on uuringud järjepidevalt näidanud, et Eesti õpilased on võrreldes teiste Euroopa ja Põhja-Ameerika õpilastega esimeste seas varase alkoholi proovimise, purju joomise ning suitsetamise ja kanepi proovimise poolest. Märkimisväärne osa käitumis- ja terviseprobleemidest on tihedalt seotud ja ennetatavad.

Koolikiusamisega seotud juhtumite kajastamisel räägitakse oluliselt vähem sellest, kuidas laste vaimset tervist ja käitumist püütakse suunata meetoditega, mis mõjuvad neile kahjulikult. Näiteks kasutades lasteaias ja koolis laste käitumise suunamiseks käitumistabeleid ja teisi sarnaseid meetodeid, mis sildistavad ja alandavad lapsi. Või kasutades hirmutamist, šokeerimist ja vägivalda, mis hoopis suurendab laste muresid ning riskide võtmist. Või soovitades lapsele enne koolitulekut palderjani anda, et ta rahulikum oleks. Neid lugusid on veel ja veel.

Aga paljud neist lugudest ei jõua avalikkuse ette. Enamasti on selliste lugude taga abivajavad lapsed ja nende perekonnad, kes püüavad iga päev keeruliste väljakutsetega toime tulla ning kelle oskused ja võimed enda õiguste ja vajaduste eest seista on väiksemad. Endiselt on levinud häbimärgistamine, hukkamõist ja müüdid - arvatakse, et vaimse tervise probleemiga lapsed on kasvatamatud, nende pered on laste haiguses või probleemides süüdi või peaksid iseseisvalt toime tulema. Tihti jääb puudu empaatiast ja hoolivusest.
Probleemide lahendamise asemel suletakse silmad
Uimastiprobleemidest ei julgeta Eestis pea üldse rääkida ning pigistatakse silmad kinni, sest meie peres sellist asja pole, meie koolis ja kogukonnas ka mitte. Äkki ignoreerides kaob ise mure ära? Sekkumine käitumisprobleemide korral tähendab enamasti pelgalt näpuviibutust - miks sa nii tegid, ära enam nii tee. Ennetuse all mõistetakse Eestis endiselt loengute tegemist, info jagamist ja ühekordseid üritusi, kuigi juba 80ndatest on teada, et ainult teadmiste edastamine ei vähenda uimastiprobleeme, kiusamist ega toeta kuidagi ka laste vaimset tervist.

Samas on tänaseks väga hästi teada, kuidas saab ennetada laste ja noorte vaimse tervise probleeme ja säästa elusid. Tulemuslikud sekkumised tugevdavad vaimset tervist ja vähendavad riskitegureid nii perekondades, haridusasutuses, kogukonnas kui ühiskonnas tervikuna. Näiteks on tõhusad vastsündinute koduvisiidid ja vanemlike oskuste arendamine. Samuti on tulemuslikud haridusasutustes laste sotsiaalsete ja enesekohaste oskuste süsteemne arendamine ning toetava ja turvalise keskkonna kujundamine. See sisaldab näiteks koolipere väärtuste, suhete, hoiakute, õpetamis- ja õppimispraktikate arendamist.
Ennetusprogrammi edasine rahastus on tagamata
Paraku on Eestis tõenduspõhiste ennetustegevuste rahastamine endiselt väga piiratud. Näiteks toetab koolides rakendatava VEPA (käitumisoskuste mäng Veel Parem) programmi elluviimist Eestis järgmise aastani Euroopa Sotsiaalfond koos Siseministeeriumiga, kuid järgmisel aastal Euroopa Sotsiaalfondi tugi lõppeb ning tegevuste jätkamiseks on rahastus riigieelarvest tagamata. VEPA on praegu ainus metoodika, mis vähendab Eestis läbiviidud uuringu põhjal laste emotsionaalseid raskuseid, käitumisraskuseid ja hüperaktiivset käitumist ning suurendab prosotsiaalset käitumist ehk laste abivalmidust, sõbralikkust ja hoolivust. Metoodika rakendamine hoiab ära ka uimastite tarvitamist ja suitsiide hilisemas eas ning parandab õpetajate klassi juhtimise ja juhendamise oskuseid.

Kuidas siis läheb meie lastel? Ilmselt võib öelda, et nii ja naa. Ja sarnaselt läheb Eesti ühiskonnal tervikuna. Paremaks saab minna ainult siis, kui hakkame reaalselt panustama tulemuslikku ennetusse laste seas.

# data[].attributes.attachment_link.title
Tervise artikkel: Kuidas läheb meie lastel? - Lõunaeestlane

# data[].attributes.attachment_link.description
Tervise Arengu Instituudi laste ja noorte valdkonna nooremteadur Karin Streimann kirjutas artikli laste vaimse tervise olukorrast, mis nähtub läbi teadusuuringute.

# data[].attributes.body
Grippi haigestus aastal 2020 4434 inimest ja aastal 2019 11668 inimest ehk grippi on eestis palju vähem. Tartumaal haigestus 2018 aastal 2095 ja 2019 2066 inimest grippi kui samal ajal Valgas 2018 haigestus 322 inimest ja 2019 225 inimest.

# data[].attributes.body
Meeste eluiga on suurenenud 3.52 ja keskmiselt elavad mehed 74.36 aastaseks ja naistel 2.23 aasta võrra ja nad elavad keskmiselt 82.77 aastaseks

# data[].attributes.body
Lehekülg räägib alkoholi ohutusest ja riskidest kui ka kuidas loobuda sellest.
1.Mitte alkoholi tarvitades, on seksuaal olukorda sattumine indiviidile parem.
2.leheküljel saab testida oma mentaalset tervist erinevate mängudega
3.Leheküljel on ka välja toodud mõned boonused tarvitamisel mõõdukuses

# data[].attributes.body
Lehekülg räägib narkootikumidest ja nende ohutusest
1.narkootikumid on ohtlikud
2.narkootikumid tekitavad kas uimestava, rahustava või nägemusi tekitava oleku
3.lehekülg aitab ka muude noorte probleemidega.

# data[].attributes.attachment_link.readable_text
Tarvitasime koos sõbrantsiga, sest elu oli igav, kurb, problemaatiline, puudus isiksuse areng, sõpruskonnas olid sõltlased. Ma loobusin tarvitamisest juba 4 kuud tagasi, sõbrants tarvitab endiselt. Me enam ei suhtle.

KARINA LUGU

# data[].attributes.attachment_link.title
Narkootikumidest, riskide vähendamisest ja abi võimalustest

# data[].attributes.attachment_link.description
Millised riskid võivad kaasneda narkootikumide tarvitamisega, kuidas neid vähendada ja kuhu pöörduda, kui sina või sinu lähedane vajab abi?